The Chief Executive of the Hong Kong Special Administrative Region, Lee Ka-chiu, today released the “Chief Executive's 2024 Policy Address” in the conference hall of the Legislative Council Complex of the Hong Kong Special Administrative Region. Li Jiachao said that the HKSAR Government will comprehensively enhance Hong Kong's clinical trial capabilities and promote the transformation of innovative biomedical achievements, including: Hong Kong and Shenzhen will jointly build a “Greater Bay Area Clinical Trial Collaboration Platform” to expand R&D networks to speed up clinical trials; establish a “Real World Research and Application Center” to promote Hong Kong and Shenzhen cooperation to combine “Hong Kong and Macau Drug Connect” data to accelerate the approval and listing of new drugs in Hong Kong; and support the development, clinical trials and application of advanced biomedical technology in Hong Kong to attract the world's top innovative enterprises and R&D institutions to settle in Hong Kong.

Zhitongcaijing · 10/16 04:01
The Chief Executive of the Hong Kong Special Administrative Region, Lee Ka-chiu, presented the “Chief Executive's 2024 Policy Address” in the conference hall of the Legislative Council Complex of the Hong Kong Special Administrative Region today. Li Jiachao said that the HKSAR Government will comprehensively enhance Hong Kong's clinical trial capabilities and promote the transformation of innovative biomedical achievements, including: Hong Kong and Shenzhen will jointly build a “Greater Bay Area Clinical Trial Collaboration Platform” to expand R&D networks to speed up clinical trials; establish a “Real World Research and Application Center” to promote Hong Kong and Shenzhen cooperation to combine “Hong Kong and Macau Drug Connect” data to accelerate the approval and listing of new drugs in Hong Kong; and support the development, clinical trials and application of advanced biomedical technology in Hong Kong to attract the world's top innovative enterprises and R&D institutions to settle in Hong Kong.